This trial is unknown!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Endothelial Dysfunction or Metabolic Syndrome
and you are
between 20 and 55
years old
2
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

It has been suggested that cardiovascular risk factors either independently or in cluster (metabolic syndrome) increase the risk of both type 2 diabetes (DM2) and cardiovascular diseases (CVD). Consumption of citrus fruits is linked to reduced cardiovascular morbidity and mortality. Hesperidin is a flavanone abundant in citrus fruit with putative vasodilator actions in vitro. While molecular mechanisms of vascular actions of hesperidin begin to be explored, no data on in vivo vascular effect of this flavanone has been ever acquired.

Provided treatments

  • Drug: Hesperidin
  • Drug: Placebo
Tris trial is registered with FDA with number: NCT00914251. The sponsor of the trial is University of Rome Tor Vergata and it is looking for 30 volunteers for the current phase.
Official trial title:
Positive Vascular Effect of Hesperidin in Subjects Affected by Metabolic Syndrome